Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.
Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical University, Yunnan, China.
J Int Med Res. 2020 Mar;48(3):300060520904847. doi: 10.1177/0300060520904847.
Chemotherapy is the standard treatment for non-small cell lung cancer (NSCLC). However, chemoresistance frequently occurs, making the treatment of NSCLC more difficult.
We combined clinical and experimental studies to establish the role of microRNA (miR)-34c in NSCLC metastasis and chemoresistance.
MiR-34c expression was significantly decreased in patients with NSCLC who showed a poor chemoresponse and metastasis. Overexpression of miR-34c sensitized NSCLC cells to paclitaxel and cisplatin both and . Furthermore, we found that NOTCH1 was target of miR-34c in NSCLC cells and played a key role in the effects of miR-34c on NSCLC.
NSCLC metastasis and chemoresistance are suppressed though the miR-34c/NOTCH1 axis. MiR-34c has important implications in the development of therapeutic strategies for metastasis and chemoresistance in NSCLC.
化疗是非小细胞肺癌（NSCLC）的标准治疗方法。然而，化疗耐药性经常发生，使得 NSCLC 的治疗更加困难。
我们结合临床和实验研究，确定了 microRNA（miR）-34c 在 NSCLC 转移和化疗耐药中的作用。
miR-34c 在化疗反应差和转移的 NSCLC 患者中表达显著降低。miR-34c 的过表达使 NSCLC 细胞对紫杉醇和顺铂的敏感性增加。此外，我们发现 NOTCH1 是 NSCLC 细胞中 miR-34c 的靶基因，并在 miR-34c 对 NSCLC 的作用中发挥关键作用。
通过 miR-34c/NOTCH1 轴抑制 NSCLC 的转移和化疗耐药。miR-34c 对 NSCLC 转移和化疗耐药的治疗策略的发展具有重要意义。
